News Releases

Year

Nov 15, 2021

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Shift to single-arm Phase 3 study for UGN-102 in bladder cancer streamlines pivotal study to form basis of FDA submission Jelmyto® net product revenue of $11.4 million for the third quarter of 2021; New patient starts in September and October outpace July and August by nearly 60% Conference call

Nov 11, 2021

UroGen Pharma Announces Upcoming 2021 Conferences

PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare

Nov 10, 2021

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 10, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at

Nov 01, 2021

UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021

Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs Company to Report Third Quarter 2021 Financial Results on November 15, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 1, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and

Oct 05, 2021

The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response (CR) Rate at Three Months 61% of Patients Remain in CR at 12 Months Data Supports

Sep 23, 2021

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 23, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual

Sep 13, 2021

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

Final data from Phase 2b OPTIMA II trial of UGN-102 showed complete and durable response for intravesical instillation in patients with low-grade intermediate risk NMIBC Long-term data from pivotal OLYMPUS trial underscores durable benefit of Jelmyto ® for adult patients with low-grade upper tract

Sep 10, 2021

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C.

Sep 03, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 3, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to

Aug 04, 2021

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Commenced Jelmyto geographic expansion

Current page 1
Page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on